Form 483

Aurobindo Pharma USA Inc Form 483, 2011-07-29

FDA issued a Form 483 to Aurobindo Pharma USA Inc on 2011-07-29 with 6 public-safe observations.

483· Form 483 issued6 observations

Aurobindo Pharma USA Inc · East Windsor, United States · Issued July 29, 2011

Overview

  • 6 public-safe observations are available for this inspection.
  • 5 structured CFR citations are represented.
  • 1 investigator is tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

29 Jul 2011
21 CFR 211.22(d)

Procedures not in writing, fully followed

Cited by Justine Tomasso

29 Jul 2011
21 CFR 314.80(b)

Failure to develop written procedures

Cited by Justine Tomasso

29 Jul 2011
21 CFR 314.80(b)

Failure to review ADE information

Cited by Justine Tomasso

29 Jul 2011
21 CFR 314.80(c)(1)(i)

Late submission of 15-day report

Cited by Justine Tomasso

29 Jul 2011
21 CFR 314.80(c)(1)(ii)

Submission of report follow-up

Cited by Justine Tomasso

Inspected site

APAurobindo Pharma USA IncEast Windsor, United States

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 314.80(b)Cited across public-safe Form 483 observations2x
21 CFR 211.22(d)Cited across public-safe Form 483 observations1x
21 CFR 314.80(c)(1)(i)Cited across public-safe Form 483 observations1x
21 CFR 314.80(c)(1)(ii)Cited across public-safe Form 483 observations1x
21 CFR 314.81(b)(1)(ii)Cited across public-safe Form 483 observations1x

Full 483 report

Get the verbatim text of all 6 observations

Every observation in full, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere